Timeline of typical observations Week 1-2: Minimal visible changes
That covers 1 or 2 of the 4 drivers which is why symptoms often linger longer than expected
Massachusetts Blue Cross Blue Shield of Massachusetts, operating within the Anthem corporate family, ended obesity medication coverage effective January 1, 2026
Pierre-Louis: And my understanding is, is that, in general, in our bodies, GLP-1s are kind of short-acting
What it looks like in practice An injectable form of DSIP typically involves either subcutaneous (under the skin) or sometimes intravenous (into the vein) administration in research settings
The common thread is the ability to adapt and innovate based on GLP-1 users changing food and beverage spending and consumption habits